Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTalphera Inc.

Talphera Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.05 USD 0.04 ( 3.96%)
Last update at 2026-11-06T21:00:00Z
VOLUME
74178
Market Cap
61.77M

Momentum Score

…

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.00
Low
1.07
High
52 Week Price Range
0.69
Low
1.57
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Talphera Inc. (TLPH) is limited, so its core business, product pipeline, and strategy are not well-documented in widely available sources. Investors may find the company of interest if it issues clearer disclosures, demonstrates commercial traction or secures partnerships or financing that could support long-term growth, and should review SEC filings and company communications for material updates before drawing conclusions.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.01
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-6.70M
Debt / Equity
0.38
ROE
-143.36%
Net Debt
0.60M
ROCE
-52.04%
Diluted EPS TTM
-0.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.36M -13.00M -10.29M 59.14M -35.09M
Net income -14.29M -13.00M -18.40M 47.76M -35.10M
Selling general administrative 7.48M 8.53M 11.99M 17.01M 30.93M
Gross profit 0.03M -6.72M 0.34M -0.82M -0.94M
Reconciled depreciation - 0.00M 0.31M 1.65M 1.97M
Ebit - -12.61M -10.15M -18.85M -32.80M
Ebitda -14.36M -12.51M -9.84M -17.20M -30.83M
Depreciation and amortization - 0.10M 0.31M 1.65M 1.97M
Operating income -13.48M -15.25M -16.89M -25.30M -35.97M
Other operating expenses 13.51M 15.25M 17.54M 20.35M 38.78M
Interest expense 0.00M 0.39M 0.13M 1.12M 2.29M
Tax provision - - 0.00M 0.01M 0.01M
Interest income 0.44M 0.68M 6.74M 1.50M 3.16M
Net interest income 0.44M 0.28M 6.60M 0.39M 0.87M
Income tax expense - - 14.85M 0.01M 0.01M
Total revenue 0.03M 0.00M 0.65M 1.77M 2.82M
Total operating expenses 13.51M 8.53M 17.54M 20.35M 35.03M
Cost of revenue - 6.72M 0.31M 2.59M 3.75M
Total other income expense net -0.88M 2.25M 6.60M 79.10M 0.87M
Net income from continuing ops -14.36M -13.00M -10.29M 59.12M -35.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 29.72M 18.24M 20.39M 47.49M 77.89M
Intangible assets 8.82M 8.82M 8.82M 8.82M -
Other current assets 0.52M 0.55M 2.17M 1.86M 2.59M
Total liab 12.68M 10.24M 6.29M 25.67M 113.79M
Total stockholder equity 17.04M 8.00M 14.11M 21.81M -35.89M
Other current liab 3.27M 1.98M 3.18M 7.04M 6.44M
Common stock 0.05M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.05M 0.02M 0.02M 0.01M 0.01M
Retained earnings -471.52M -457.23M -444.23M -425.83M -473.58M
Cash 5.89M 8.86M 5.72M 15.28M 7.66M
Total current liabilities 3.81M 2.65M 4.51M 13.77M 18.51M
Current deferred revenue - - - 0.12M 0.09M
Net debt 0.60M -2.34M -5.72M -9.91M 10.96M
Short term debt - - - 5.36M 9.86M
Short long term debt - - - 5.36M 8.80M
Short long term debt total 6.50M 6.53M - 5.36M 18.62M
Other stockholder equity 488.51M 465.21M 458.31M 447.63M 437.68M
Total current assets 20.90M 9.42M 11.56M 24.57M 50.49M
Short term investments 14.49M 0.00M 3.66M 0.49M 38.97M
Net receivables - - - 0.31M 0.16M
Long term debt - - - - 5.01M
Inventory - - - 1.18M 1.11M
Accounts payable 0.54M 0.67M 1.34M 1.26M 2.12M
Non currrent assets other 8.82M 8.82M 0.02M 0.25M 7.17M
Non current assets total 8.82M 8.82M 8.84M 22.92M 27.40M
Capital lease obligations - - - 4.66M 4.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -14.35M 3.78M -0.53M 36.45M -26.12M
Total cashflows from investing activities -14.35M 3.78M - - -
Net borrowings - 0.00M - - -
Total cash from financing activities 22.74M 12.04M 3.47M -0.51M 41.51M
Net income -14.29M -13.00M -18.40M 47.76M -35.10M
Change in cash -2.97M 3.14M -14.55M 7.61M -14.61M
Begin period cash flow 8.86M 5.72M 20.27M 12.66M 27.27M
End period cash flow 5.89M 8.86M 5.72M 20.27M 12.66M
Total cash from operating activities -11.36M -12.68M -17.49M -28.33M -30.00M
Issuance of capital stock - 0.00M 8.86M 8.22M 50.28M
Depreciation -0.14M -0.12M 0.31M 1.65M 1.97M
Change to inventory - 0.00M 0.06M -0.11M -0.29M
Change to account receivables - - -0.19M -0.15M 0.47M
Sale purchase of stock - - -0.02M -0.32M -0.25M
Other cashflows from financing activities 22.74M 12.04M -0.02M -0.06M -0.25M
Capital expenditures 0.00M 0.00M 0.10M 0.36M 1.83M
Change in working capital 1.08M -0.22M -1.54M -1.39M 0.20M
Stock based compensation 0.70M 0.99M 1.73M 2.89M 4.61M
Other non cash items 1.29M -0.32M -1.79M -84.95M -2.50M
Free cash flow -11.36M -12.68M -17.59M -28.70M -31.83M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TLPH
Talphera Inc.		 0.04
3.96%		 1.05 - 1.02 61767.90 4.47 47287.19 0.11
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Talphera Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

1850 Gateway Drive, San Mateo, CA, United States, 94404

650 216 3500

https://talphera.com

12

Name Title Year Born
Mr. Vincent J. Angotti CEO & Director 1968
Dr. Pamela Pierce Palmer M.D., Ph.D. Co-Founder & Chief Medical Officer 1963
Mr. Raffi Mark Asadorian Chief Financial Officer 1969
Mr. Anil N. Dasu Chief Engineering Officer 1963
Dr. Shakil Aslam M.D. Chief Medical Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…